Physician preferences for non-metastatic castration-resistant prostate cancer treatment

BACKGROUND: Recent approvals of second-generation androgen receptor inhibitors (SGARIs) have changed the treatment landscape for non-metastatic castration-resistant prostate cancer (nmCRPC). These SGARIs have similar efficacy but differ in safety profiles. We used a discrete choice experiment to exp...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Urol
Main Authors: Srinivas, Sandy, Mohamed, Ateesha F., Appukkuttan, Sreevalsa, Botteman, Marc, Ng, Xinyi, Joshi, Namita, Horodniceanu, Erica, Waldeck, A. Reginald, Simmons, Stacey J
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7310549/
https://ncbi.nlm.nih.gov/pubmed/32571276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12894-020-00631-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados